DexCom, Inc. is a company that develops, manufactures, produces, and distributes

continuous glucose monitor A continuous glucose monitor (CGM) is a device used for monitoring blood glucose on a continual basis by insulin-requiring people with diabetes, e.g. people with type I, type II diabetes or other types of diabetes (e.g. gestational diabetes). A ...

ing (CGM) systems for

diabetes Diabetes, also known as diabetes mellitus, is a group of metabolic disorders characterized by a high blood sugar level ( hyperglycemia) over a prolonged period of time. Symptoms often include frequent urination, increased thirst and increased ap ...

management. It operates internationally with headquarters in

San Diego, California San Diego ( , ; ) is a city on the Pacific Ocean coast of Southern California located immediately adjacent to the Mexico–United States border. With a 2020 population of 1,386,932, it is the eighth most populous city in the United States ...

, and has a manufacturing facility in

Mesa, Arizona Mesa ( ) is a city in Maricopa County, Arizona, Maricopa County, in the U.S. state of Arizona. It is the most populous city in the East Valley (Phoenix metropolitan area), East Valley section of the Phoenix Metropolitan Area. It is bordered by ...

and

Batu Kawan Batu Kawan ( Jawi: باتو كاون) is an island in the city of Seberang Perai, Penang, Malaysia. It is geographically separated from the rest of Seberang Perai by the Jawi and Tengah rivers. , Batu Kawan contained a population of 5,537. Long ...

Malaysia Malaysia ( ; ) is a country in Southeast Asia. The federation, federal constitutional monarchy consists of States and federal territories of Malaysia, thirteen states and three federal territories, separated by the South China Sea into two r ...

History

Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S.

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respon ...

(FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System, in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and

Animas Corporation Animas Corporation was an American company that specialized in making insulin pumps. The company was founded by Katherine Crothall in 1996, had its initial public offering in May 2004 under the ticker symbol 'PUMP', and was ultimately acquired by ...

as well as a development agreement with

Edwards Lifesciences Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue wi ...

for a continuous glucose monitor in the

intensive care unit 220px, Intensive care unit An intensive care unit (ICU), also known as an intensive therapy unit or intensive treatment unit (ITU) or critical care unit (CCU), is a special department of a hospital or health care facility that provides intensiv ...

hospital environment. During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring system, from the FDA. This product received a

CE mark On commercial products, the letters CE (as the logo ) mean that the manufacturer or importer affirms the good's conformity with European health, safety, and environmental protection standards. It is not a quality indicator or a certificat ...

in November 2009. In 2013, development work for integration with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its forthcoming G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. The G5 was approved in 2016 by the

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

for use as a standalone device, while the G6 gained approval in 2018. Dexcom's first G-series CGM, the G4 Platinum, received a CE mark and FDA approval in 2012 for adults ages 18 and over. This device improved hypoglycemic accuracy by 30%. It also offered a longer range of transmission between the sensor and receiver, as well as a color LCD. The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014. Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps. The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, the G5 has

Bluetooth Bluetooth is a short-range wireless technology standard that is used for exchanging data between fixed and mobile devices over short distances and building personal area networks (PANs). In the most widely used mode, transmission power is limi ...

integrated into its transmitter, enabling it to send data to a mobile device. This allows for use of the device without the standalone receiver. The Dexcom G5 received a CE mark in September 2015.

Partnerships

Dexcom entered a non-exclusive agreement with

Tandem Diabetes Care Tandem Diabetes Care is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy. History In 2006, a group of engin ...

, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem's t:slim X2 insulin pump and the Dexcom G6 to "to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes." In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen into both companies' software applications. Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo’s platform. This integration allowed Livongo to incorporate the CGM data along with other patient data. In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet’s tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery. This allowed the ability to adjust insulin doses based on Insulet’s algorithm or through their smartphone. The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for

diabetes management The term ''diabetes'' includes several different metabolic disorders that all, if left untreated, result in abnormally high concentration of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces ...

References

External links

* {{authority control American companies established in 1999 Health care companies established in 1999 Health care companies based in California Medical technology companies of the United States Manufacturing companies based in San Diego Medical device manufacturers 2005 initial public offerings 1999 establishments in California